Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2019 | 12:59pm EDT
FILE PHOTO: Logo of U.S. pharmaceutical corporation Pfizer Inc. is seen in Zurich

(Reuters) - Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Shares of the largest U.S. drugmaker rose more than 3 percent to $40.84.

As blockbuster pain medicine Lyrica faces competition from generics, growth at Pfizer has slowed, driving the company to invest in cancer drugs and gene therapies as it works to launch new medicines.

Pfizer has pointed to experimental drugs like heart medicine tafamidis, a potential blockbuster it expects to be approved within the next few months, as part of its plan to grow sales, and said it will continue to consider bolt-on acquisitions worth "a few billion dollars."

But it has also suffered setbacks among other candidates in its plan to launch up to 15 new drugs with at least $1 billion (£769 million) annual sales potential each over a five-year period. That included disappointing clinical results for non-opioid pain drug tanezumab, as well as two other discontinued trials.

"We are not overly reliant on a single pipeline opportunity," Chief Executive Officer Albert Bourla, who succeeded CEO Ian Read at the start of the year, said on a conference call with analysts.

In a phone interview with Reuters, Bourla said he expects a high rate of approvals.

"If you use the average industry success rate, we should do more," he said.

"So far I have been very pleased," he said, citing recent positive results in five late-stage and three midstage clinical trials.

Pfizer said its business development priorities are now focused on enhancing its pipeline of drugs in development.

Meanwhile Eliquis, which it shares with Bristol-Myers Squibb, and Prevnar keep putting up big sales.

The blood clot preventer had sales of $1.01 billion in the quarter, above consensus estimates of $935 million. Prevnar sales of $1.49 billion topped Wall Street estimates of $1.39 billion.

The company expects mid-single-digit operational revenue growth post-2020 through 2025, Bourla said.

Two of Pfizer's U.S. rivals also reported first-quarter results on Tuesday.

Strong vaccine and cancer drug sales helped Merck & Co top Wall Street earnings expectations and sent its shares higher. But Eli Lilly and Co shares fell after it reported sales of closely-watched diabetes and psoriasis treatments that fell short of analyst estimates.

Pfizer pushed its 2019 adjusted earnings forecast marginally higher and now expects $2.83 to $2.93 per share, up from a prior projection of $2.82 to $2.92. It maintained its full-year revenue forecast of $52 billion to $54 billion.

Excluding special items, the company earned 85 cents per share, beating analysts' estimate of 75 cents.

Net income rose 9 percent to $3.88 billion, or 68 cents per share, in the first quarter.

Revenue rose 1.6 percent to $13.12 billion, ahead of estimates of $12.99 billion.

(Reporting by Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Patrick Graham, Shinjini Ganguli and Bill Berkrot)

By Tamara Mathias and Michael Erman

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
06/15PFIZER : Sosei Heptares secures second $3m milestone payment in collaboration wi..
06/14Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece
06/14ENDONOVO THERAPEUTICS : Announces National Rollout of SofPulse Post-Operative Op..
06/14G1 THERAPEUTICS : Announces Updates to Board of Directors
06/13GSK signs up gene-editing pioneers in drug discovery alliance
06/13PFIZER : Announces Results from XELJANZ XR ORAL Shift Study, the First Phase 3b/..
06/12PFIZER : Says Results Positive in Rheumatoid Arthritis Study
06/12PFIZER : Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The ..
06/11PFIZER : Sosei Heptares to get $3m Pfizer milestone payment
06/11SOSEI : Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It ..
More news
Financials ($)
Sales 2019 53 351 M
EBIT 2019 19 750 M
Net income 2019 13 323 M
Debt 2019 26 335 M
Yield 2019 3,34%
P/E ratio 2019 17,84
P/E ratio 2020 16,29
EV / Sales 2019 4,97x
EV / Sales 2020 4,87x
Capitalization 239 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 45,6 $
Spread / Average Target 6,2%
EPS Revisions
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.63%233 072
JOHNSON & JOHNSON9.04%348 981
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893